ReviewF1000Research2016
Cell biology and genetics of minimal change disease.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- The clinical significance of the naples prognostic score in adult idiopathic nephrotic syndrome: a retrospective study.Irish journal of medical science · 2026Article
- The Influence of the Main Components of Tobacco Smoke, E-Cigarettes, and Air Pollutants on the Development of Glomerulonephritis.Journal of clinical medicine · 2026Review
- Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy.Clinical kidney journal · 2026Review
- Article
- Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.International journal of molecular sciences · 2024Review
- Anti-Tumor Necrosis Factor Treatment for Glomerulopathy: Case Report and Review of Literature.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Association of ABCB1(Rs10276036, C/T) Gene, IL-18, and TNFα as Risk Factors for Nephrotic Syndrome Incidence.Reports of biochemistry & molecular biology · 2024Article
- Acute pulmonary embolism with arrhythmia associated with minimal change disease in adults: a case report.Frontiers in cardiovascular medicine · 2023Article
- Minimal Change Disease in an Adult: A Case Report.JNMA; journal of the Nepal Medical Association · 2022Article
- Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia.Frontiers in medicine · 2022Article
- Steroid Minimization in Adults with Minimal Change Disease.Glomerular diseases · 2021Review
- The important roles and molecular mechanisms of annexin AAnnals of translational medicine · 2021Article
- The immune cell landscape of peripheral blood mononuclear cells from PNS patients.Scientific reports · 2021Article
- Biopsy or Biomarker? Children With Minimal Change Disease Have a Distinct Profile of Urinary Epidermal Growth Factor.Frontiers in pediatrics · 2021Article
- Increased number and activation of peripheral basophils in adult-onset minimal change disease.Journal of cellular and molecular medicine · 2020Article
- Interleukin-18 binding protein attenuates renal injury of adriamycin-induced mouse nephropathy.International journal of clinical and experimental pathology · 2019Article
- Article
- Keeping nephrotic syndrome on the emergency department edema differential: A case report.World journal of emergency medicine · 2019Article
- Genetics of childhood steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017Review
- Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.BioMed research international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Minimal change disease (MCD) is an important cause of nephrotic syndrome and is characterized by massive proteinuria and hypoalbuminemia, resulting in edema and hypercholesterolemia. The podocyte plays a key role in filtration and its disruption results in a dramatic loss of function leading to proteinuria. Immunologic disturbance has been suggested in the pathogenesis of MCD. Because of its clinical features, such as recurrent relapse/remission course, steroid response in most patients, and rare familial cases, a genetic defect has been thought to be less likely in MCD. Recent progress in whole-exome sequencing reveals pathogenic mutations in familial cases in steroid-sensitive nephrotic syndrome (SSNS) and sheds light on possible mechanisms and key molecules in podocytes in MCD. On the other hand, in the majority of cases, the existence of circulating permeability factors has been implicated along with T lymphocyte dysfunction. Observations of benefit with rituximab added B cell involvement to the disease. Animal models are unsatisfactory, and the humanized mouse may be a good model that well reflects MCD pathophysiology to investigate suggested "T cell dysfunction" directly related to podocytes in vivo. Several candidate circulating factors and their effects on podocytes have been proposed but are still not sufficient to explain whole mechanisms and clinical features in MCD. Another circulating factor disease is focal segmental glomerulosclerosis (FSGS), and it is not clear if this is a distinct entity, or on the same spectrum, implicating the same circulating factor(s). These patients are mostly steroid resistant and often have a rapid relapse after transplantation. In clinical practice, predicting relapse or disease activity and response to steroids is important and is an area where novel biomarkers can be developed based on our growing knowledge of podocyte signaling pathways. In this review, we discuss recent findings in genetics and podocyte biology in MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.